1
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


3

4
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of akt activity. December 29, 2011: US20110319443-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


5
Kevin Rodzinak
Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J Rodzinak, Toshihiro Sakamoto, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activity. April 21, 2011: US20110092511-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


6
Kevin Rodzinak
Mark E Layton, Kevin J Rodzinak, Michael J Kelly, Philip E Sanderson: 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists. Merck And Co, December 20, 2007: US20070293515-A1

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, ...


7
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


8
Kevin Rodzinak
Mark E Layton, Kevin J Rodzinak, Philip E Sanderson: Inhibitors of akt activity. Merck And Co, January 28, 2010: US20100022573-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


9
Theresa M Williams, Terrence M Ciccarone, Walfred S Saari, John S Wai, William J Greenlee, Suresh K Balani, Mark E Goldman, Anthony D Theoharides deceased, Jacob M Hoffman Jr, William C Lumma Jr, Joel R Huff, Clarence S Rooney, Philip E Sanderson: Inhibitors of HIV reverse transcriptase. Merck & Co, Carol S Quagliato, Roy D Meredith, Charles M Caruso, June 18, 1996: US05527819 (38 worldwide citation)

Novel indole compounds inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, ...


10
William C Lumma, Roger M Freidinger, Stephen F Brady, Philip E Sanderson, Dong Mei Feng, Terry A Lyle, Kenneth J Stauffer, Thomas J Tucker, Joseph P Vacca: Pyrrolidine thrombin inhibitors. Merck & Co, Richard S Parr, Melvin Winokur, April 23, 1996: US05510369 (30 worldwide citation)

Compounds of the invention have the following structure: ##STR1## for example ##STR2## These compounds inhibit thrombin and associated thrombosis.



Click the thumbnails below to visualize the patent trend.